Abatacept and Ptcy with Cyclosporine or Sirolimus As Gvhd Prophylaxis in Haploidentical HCT: Understanding the Immunobiology in Improving the Outcome.

Abatacept (Abata, CTLA4Ig), an inhibitor of a key costimulation pathway has recently been approved for GVHD prophylaxis following unrelated donor HCT in combination with CNI/MTX. Since 2015, we had developed a novel protocol combining Abata and PTCy for HCT from haploidentical family donors. We analysed the impact of donor immunogenetics and immune reconstitution on the long-term outcome of 182 patients receiving HFD-HCT on this protocol.

https://www.astctjournal.org/article/S2666-6367(23)01817-1/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Prakash Baligar, Hema Malini Aiyer, Bhudev C Das, Subhrajit Biswas, Suparno Chakrabarti Tags: 55 Source Type: research